MF

Mathias Frederiksen

Principal @ Novartis Venture Fund

Basel, Basel

Invests in

Stages:

  • Min Investment:

    $5,000,000.00
  • Max Investment:

    $10,000,000.00
  • Target Investment:

    $7,500,000.00

Work Experience

  • Principal

    2023

  • Associate

    2022 - 2023

    Discover and nurture biotech start-ups from seed to IPO.

  • Board Observer

    2024

  • Director Board of Directors

    2023

    Helping FMP to realize breakthrough therapies in neurodegeneration

  • Board Observer

    2023

  • Board Observer

    2022

    The UZH Life Sciences Fund is a partnership between the UZH Foundation and Novartis Venture Fund to seed UZH spinouts in the field of life sciences.

  • Board Observer

    2022

    Helping LOQUS23 amazing team to bring small molecule therapeutics to patients suffering from triplet expansion disorders like Huntington's Disease.

  • Associate Director and Group Leader Chomatin Chemical Biology

    2020 - 2022

    Directing a research program aimed at elucidating the role of epigenetic regulation in human disease to uncover novel paradigms for chromatin-focused drug discovery.

  • Senior Investigator II

    2018 - 2020

    Group leader Chromatin Chemical Biology: Directing a research program aimed at elucidating the role of epigenetic regulation in human disease to uncover novel paradigms for chromatin-focused drug discovery.

  • Senior Investigator I

    2014 - 2018

    Lab-head Global Discovery Chemistry - Chemogenetics Chemical proteomics, new target discovery, new chemical technologies at the interface of chemistry and biology.

  • Investigator III

    2010 - 2014

    Lab-head Global Discovery Chemistry - Chemogenetics Chemical proteomics, new target discovery, new chemical technologies at the interface of chemistry and biology.

  • Research Investigator II

    2007 - 2009

    Lab-head Global Discovery Chemistry - Neuroscience Development of novel therapeutic agents against Neurodegenerative disease.

  • Research Investigator I

    2005 - 2007

    Lab-head Global Discovery Chemistry - Neuroscience Development of novel therapeutic agents against Neurodegenerative disease.

2003 - 2004

  • Post-doctoral Research Investigator

    2003 - 2004

    Research Fellow in the laboratories of Professor Barry Trost, working on Pd-catalyzed asymmetric alkylation reactions and total synthesis. Funded by GSK Postdoctoral Fellowship

  • PhD Candidate

    1998 - 2002

    PhD candidate in the laboratories of Professor Tony Barrett. Focus of research was development of macrolactonization protocols amenable to solid-phase synthesis of macrolides as well as development of other solid-phase methodologies. Funded by Norwegian Research Council